Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, Calif., has announced plans to acquire Oobli Inc., a Davis, Calif.-based developer of fermentation-derived sweet proteins. The companies said the transaction is expected to close in the coming weeks.
The acquisition would combine Amyris’ scientific and manufacturing capabilities with Oobli’s expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion aimed at accelerating its presence in protein- and peptide-based solutions across end markets.
Complementary platforms
Amyris CEO Kathy Fortmann described Oobli as a commercial and technology platform that complements Amyris’s own. According to Fortmann, Oobli is positioned to change how sweetness reaches the market, and Amyris aims to apply its commercial scale and resources to accelerate that effort. She also said combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the combined company’s work in food and beverage, personal care, flavor and fragrance, agriculture and other areas.
Oobli’s commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. Oobli has spent the past decade refining a fermentation process for producing sweet proteins naturally found in rare fruits and berries near the equator. The company says its sweet proteins are the first of their kind in the sugar-reduction category.
Product and regulatory position
According to the companies, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says this allows them to deliver sweetness without gut disruption or blood sugar spikes.
Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor.
The companies see growing consumer awareness of metabolic health and the benefits of sugar reduction as a driver for sweet proteins. They say the ingredients can help brands reduce sugar across categories including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.
Leadership views and continuity
Oobli CEO Ali Wing said the company has sought a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would provide the scale and resources to pursue Oobli’s ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann said Amyris has found that biomanufactured solutions succeed when they align with consumer demand and market needs. She said Oobli’s platform supports brands seeking sweet taste, sugar reduction and a clean label at the same time, and she welcomed the Oobli team to Amyris.
Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli’s sweet-protein portfolio expands within the company.
